PE20030042A1 - Derivados de dipeptido como inhibidores de enzima convertidora de angiotensina y endopeptidasa neutra - Google Patents

Derivados de dipeptido como inhibidores de enzima convertidora de angiotensina y endopeptidasa neutra

Info

Publication number
PE20030042A1
PE20030042A1 PE2002000407A PE2002000407A PE20030042A1 PE 20030042 A1 PE20030042 A1 PE 20030042A1 PE 2002000407 A PE2002000407 A PE 2002000407A PE 2002000407 A PE2002000407 A PE 2002000407A PE 20030042 A1 PE20030042 A1 PE 20030042A1
Authority
PE
Peru
Prior art keywords
alkyl
carbocyclic
cycloalkyl
methylbutanoylamine
methylpropionyl
Prior art date
Application number
PE2002000407A
Other languages
English (en)
Spanish (es)
Inventor
Cynthia Anne Fink
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20030042A1 publication Critical patent/PE20030042A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PE2002000407A 2001-05-15 2002-05-15 Derivados de dipeptido como inhibidores de enzima convertidora de angiotensina y endopeptidasa neutra PE20030042A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29108801P 2001-05-15 2001-05-15
US33957501P 2001-12-11 2001-12-11

Publications (1)

Publication Number Publication Date
PE20030042A1 true PE20030042A1 (es) 2003-02-28

Family

ID=26966569

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000407A PE20030042A1 (es) 2001-05-15 2002-05-15 Derivados de dipeptido como inhibidores de enzima convertidora de angiotensina y endopeptidasa neutra

Country Status (23)

Country Link
US (3) US6777443B2 (enExample)
EP (2) EP1392720A2 (enExample)
JP (1) JP4390458B2 (enExample)
KR (1) KR100908152B1 (enExample)
CN (1) CN1649893A (enExample)
AR (1) AR035890A1 (enExample)
AU (1) AU2002314067B2 (enExample)
BR (1) BR0209652A (enExample)
CA (1) CA2449292A1 (enExample)
CO (1) CO5540347A2 (enExample)
CZ (1) CZ20033077A3 (enExample)
HU (1) HUP0304084A3 (enExample)
IL (1) IL158772A0 (enExample)
MX (1) MXPA03010403A (enExample)
MY (1) MY127495A (enExample)
NO (1) NO20035084L (enExample)
NZ (1) NZ529438A (enExample)
PE (1) PE20030042A1 (enExample)
PL (1) PL366786A1 (enExample)
RU (1) RU2298559C2 (enExample)
SK (1) SK14032003A3 (enExample)
TW (1) TWI295996B (enExample)
WO (1) WO2002092622A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
PL366610A1 (en) * 2001-07-06 2005-02-07 Teva Pharmaceutical Industries Ltd. Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
BR0212899A (pt) * 2001-09-21 2004-11-03 Novartis Ag Compostos orgânicos
ES2290429T3 (es) * 2002-01-17 2008-02-16 Novartis Ag Composiciones farmaceuticas que comprenden valsartan e inhibidores de nep.
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
ATE409476T1 (de) * 2002-06-13 2008-10-15 Novartis Pharma Gmbh Calciumsalze von statinen aus indol
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CN101080232A (zh) * 2004-12-15 2007-11-28 索尔瓦药物有限公司 包含NEP-抑制剂、内源性内皮素产生系统的抑制剂和HMG CoA还原酶抑制剂的药物组合物
WO2006097570A1 (en) * 2005-03-14 2006-09-21 Orion Corporation A combination treatment for enhancing diuresis
US7390789B2 (en) * 2005-09-13 2008-06-24 William H Simmons Thio-containing inhibitors of aminopeptidase P, and compositions thereof
US7400236B2 (en) 2005-10-21 2008-07-15 Gm Global Technology Operations, Inc. Vehicular lane monitoring system utilizing front and rear cameras
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20120157387A1 (en) * 2006-11-28 2012-06-21 Apotex Technologies Inc. Orally bioavailable d-gamma-glutamyl-d-tryptophan
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP2200975A1 (en) 2007-09-07 2010-06-30 Theravance, Inc. Dual-acting antihypertensive agents
EP2225210B1 (en) 2007-12-11 2012-04-25 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
US7989484B2 (en) 2008-04-29 2011-08-02 Theravance, Inc. Dual-acting antihypertensive agents
WO2010011821A2 (en) * 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
EP2451782B1 (en) 2009-07-07 2016-11-09 Theravance Biopharma R&D IP, LLC Dual-acting pyrazole antihypertensive agents
US8372984B2 (en) 2009-07-22 2013-02-12 Theravance, Inc. Dual-acting oxazole antihypertensive agents
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
JP2014510734A (ja) * 2011-03-31 2014-05-01 アポテックス テクノロジーズ インコーポレイテッド D−ガンマ−グルタミル−d−トリプトファンおよびd−ガンマ−グルタミル−l−トリプトファンのプロドラッグ
US9212206B1 (en) * 2014-11-24 2015-12-15 William H Simmons 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2019213386A1 (en) * 2018-05-04 2019-11-07 New Mexico Tech University Research Park Corporation Proteasome inhibitors
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法
WO2024230583A1 (zh) * 2023-05-05 2024-11-14 上海济煜医药科技有限公司 一种短肽类化合物及其制备方法和医药应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432307A1 (de) * 1984-09-03 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Aminosaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
WO1991008199A1 (fr) 1989-11-27 1991-06-13 Santen Pharmaceutical Co., Ltd. Derive d'acide amine
FR2679564A1 (fr) 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
DE69314718T2 (de) 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
US5432186A (en) 1993-11-16 1995-07-11 Ciba-Geigy Corporation Cyclic amino acid derivatives
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
WO1996030395A2 (en) 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
JP3156794B2 (ja) * 1995-04-25 2001-04-16 富士薬品工業株式会社 高水溶性メタロプロテイナーゼ阻害剤
EP0824544B1 (en) 1995-05-10 2003-04-16 Darwin Discovery Limited Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
EP0830368A1 (en) * 1995-06-07 1998-03-25 Genta Incorporated Novel carbamate-based cationic lipids
US6245809B1 (en) * 1996-12-09 2001-06-12 Cor Therapeutics Inc. Integrin antagonists
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19745151A1 (de) 1997-10-14 1999-04-15 Basf Ag Neue Verbindungen zur Behandlung von Krankheiten, die mit der biologischen Wirkung von Endothelin assoziiert sind
FR2770844A1 (fr) 1997-11-10 1999-05-14 Inst Nat Sante Rech Med Inhibiteurs de toxines clostridiales et compositions pharmaceutiques les contenant
CA2309792A1 (en) * 1997-11-12 1999-05-20 William C. Shakespeare Novel signal transduction inhibitors, compositions containing them
CA2324251A1 (en) 1998-04-23 1999-11-04 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
IL138246A0 (en) 1998-04-23 2001-10-31 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme
DK1140984T3 (da) 1998-12-31 2003-05-26 Aventis Pharma Inc Selektive inhibitorer af MMP-12
FR2788526B1 (fr) 1999-01-20 2002-07-05 Inst Nat Sante Rech Med Composes tripeptidiques utiles a titre d'hinhibiteurs selectifs de l'aminopeptidase a et compositions pharmaceutiques correspondantes
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
GB9917909D0 (en) * 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
EA200200301A1 (ru) * 1999-08-27 2002-08-29 Сайтовиэ, Инк. ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ
US6803383B2 (en) * 2000-03-27 2004-10-12 The Scripps Research Institute Inhibition of angiogenesis and tumor growth
AU2001287289A1 (en) 2000-04-03 2001-10-15 Bristol-Myers Squibb Company Vasopeptidase inhibitors to treat isolated systolic hypertensions
AR032316A1 (es) 2000-04-12 2003-11-05 Novartis Ag Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica
US20020013307A1 (en) 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Also Published As

Publication number Publication date
EP1392720A2 (en) 2004-03-03
TWI295996B (en) 2008-04-21
RU2298559C2 (ru) 2007-05-10
BR0209652A (pt) 2004-07-13
KR100908152B1 (ko) 2009-07-16
US6992105B2 (en) 2006-01-31
CZ20033077A3 (cs) 2004-02-18
JP2005504011A (ja) 2005-02-10
NO20035084L (no) 2004-01-15
PL366786A1 (en) 2005-02-07
HUP0304084A2 (hu) 2004-12-28
US20060058242A1 (en) 2006-03-16
CN1649893A (zh) 2005-08-03
AU2002314067B2 (en) 2006-03-16
RU2003134153A (ru) 2005-06-10
US20020183260A1 (en) 2002-12-05
WO2002092622A2 (en) 2002-11-21
HUP0304084A3 (en) 2010-10-28
CA2449292A1 (en) 2002-11-21
CO5540347A2 (es) 2005-07-29
WO2002092622A8 (en) 2004-01-22
US20040235754A1 (en) 2004-11-25
NO20035084D0 (no) 2003-11-14
US6777443B2 (en) 2004-08-17
WO2002092622A3 (en) 2003-04-10
MY127495A (en) 2006-12-29
KR20030096401A (ko) 2003-12-24
EP2239268A1 (en) 2010-10-13
IL158772A0 (en) 2004-05-12
SK14032003A3 (sk) 2004-06-08
MXPA03010403A (es) 2004-03-09
JP4390458B2 (ja) 2009-12-24
AR035890A1 (es) 2004-07-21
NZ529438A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
PE20030042A1 (es) Derivados de dipeptido como inhibidores de enzima convertidora de angiotensina y endopeptidasa neutra
EA200301094A1 (ru) Аминопроизводные как ингибиторы протеазы
PE20070798A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
KR100462974B1 (ko) 트롬빈 억제제
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20070135A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20221336A1 (es) Compuestos triciclicos sustituidos
AR035659A1 (es) Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
TR200201752T2 (tr) Dipeptid nitril katepsin K inhibitörleri.
RU96120088A (ru) Антитромботические агенты
EA200602290A1 (ru) Лиганды crth2 рецептора и их применение
ES2367576T3 (es) Nuevos compuestos como moduladores de receptores opioides.
EA200600348A1 (ru) Новые соединения
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
PE20060999A1 (es) Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii
TR200103067T2 (tr) Renin inhibitörleri
PE20060823A1 (es) Compuestos de arilsulfonamida como moduladores de receptores cck1/cck2
DK0586806T3 (da) Anvendelse af 2-(N-(2-aminoethyl)-amino)-eddike-syrederivater til behandling af sygdomme, der er betinget af den ikke-enzym
PE20060692A1 (es) Inhibidores bace
PE20171443A1 (es) Derivados de carboxamida
EA200400994A1 (ru) Новые 1,2,3-замещенные производные индолизина, являющиеся ингибиторами факторов роста фибробластов, способ их получения и фармацевтические композиции, содержащие их
PE20021013A1 (es) Dihidropirimidinas-5-ciano sustituidos como agentes antiproliferativos
NO871861L (no) Fremgangsmaate for fremstilling av nye dopamin beta-hydroxylase inhibitorer.
PE20010951A1 (es) Inhibidores de la proteinasa c del procolageno
EA200400110A1 (ru) НОВЫЙ СПОСОБ СИНТЕЗА СОЕДИНЕНИЙ (2S, 3aS, 7aS )-1-[(S)-АЛАНИЛ]-ОКТАГИДРО-1H-ИНДОЛ-2-КАРБОНОВОЙ КИСЛОТЫ И ПРИМЕНЕНИЕ В СИНТЕЗЕ ПЕРИНДОПРИЛА

Legal Events

Date Code Title Description
FC Refusal